Skip to content

POWER Myocardial Fatigue Study: a Biomechanical Assessment of Contractility of Human Myocardium

Profiling Biomechanical Responses and Workload of the Human Myocardium to Explore the Concept of Myocardial Fatigue and Reversibility

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04899635
Acronym
POWER
Enrollment
100
Registered
2021-05-24
Start date
2021-08-03
Completion date
2025-04-30
Last updated
2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exhaustion; Heart, Fatigue; Muscle, Heart, Heart Failure, Myocardial Dysfunction

Keywords

Myocardial Fatigue, Preload, Afterload, Cardiac Work-loop, Cardiomyocytes, Biomechanical model

Brief summary

To gain a comprehensive understanding of the biomechanical behaviour of human heart to explore the concept of myocardial fatigue in response to a temporal range of preload, afterload and drug-induced inotropy using in-vitro contractile assays.

Detailed description

A continuum of pathological states from fatigue, injury to damage of the myocardium has been proposed which complements the continuous spectrum of HF and reconciles the seemingly disparate plethora of mechanisms behind the pathophysiology of HF. Unlike skeletal muscle where mechanical stress can be readily removed upon fatigue, an impaired left ventricle continues to receive preload from the right ventricle and cannot rest, maintaining cardiac output only at the expense of increasing filling pressures (as in HF with preserved ejection fraction). If concurrently faced with high afterload from vascular stiffness, ventricular-arterial decoupling occurs, driving mechanical inefficiency and diminishing cardiac output (as in HF with reduced ejection fraction). Chances of recovery is linked to the degree of fatigue, cardiomyocyte loss and replacement with non-contractile fibrosis. Assuming that the myocardium is in a state of chronic fatigue before reaching advanced stages of fibrosis, cases such as aortic stenosis or hypertensive heart disease may potentially be reversible if the pathological load is promptly removed. This study will be re-synthesizing existing knowledge of the biomechanical behaviour of healthy and diseased cardiac myocytes and muscle in a new light of the theoretical constructs of myocardial fatigue, aligned with the existing energy-starvation theory. It will be a proof-of-concept study. Just as Frank-Starling's relationship between preload and cardiac output emerged from pre-clinical studies on muscle behaviour with subsequently major clinical implications, this study represents a necessary stepping stone to adding a new layer of insight into the pathophysiology of heart failure (HF).

Interventions

OTHERIn-vitro contractile fatigue protocol

Using contractility assays for muscle slices or the work-loop assay for isolated heart cells, the tissue preparation will undergo a series of contraction and relaxation under varying levels of preload, afterload, stimulation frequency and under other experimental conditions such as drug-induced inotropism.

Sponsors

Coventry University
CollaboratorOTHER
University Hospitals Coventry and Warwickshire NHS Trust
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years

Inclusion criteria

* All adult patients between 18 to 85-years old undergoing open-heart surgery who can undergo the consent process for the study * Healthy donor hearts that are deemed non-transplantable and consent received from a legal representative

Exclusion criteria

This criterion is kept to a minimum since the availability of human myocardial samples is finite and dependent on the limited number of patients undergoing cardiac surgery annually within the local hospital. * Patients who do not have the mental capacity to undergo the consent process * For the safety of researchers, patients with evidence of ongoing blood-borne infections such as HIV, or a recent positive test for COVID-19 (within 10 days of last PCR test).

Design outcomes

Primary

MeasureTime frameDescription
Changes in the force generated by the muscle cell and/or muscle sliceWithin a day for each experimentThis will be based on the effects of changing load and/or exposure to drug-induced inotropic effects
Changes in the velocity of shortening by the muscle cell and/or muscle sliceWithin a day for each experimentThis will be based on the effects of changing load and/or exposure to drug-induced inotropic effects
Changes in the end-systolic force-length relationship of the muscle cell and/or muscle sliceWithin a day for each experimentThis will be based on the effects of changing load and/or exposure to drug-induced inotropic effects, and calculated by integrating the above force and length changes.

Secondary

MeasureTime frameDescription
Changes in the phosphorylation potentialWithin a day for each experimentThis will be calculated by determining the above concentration of adenosine triphosphate and its metabolic by-product including inorganic phosphate, at different times of the contraction fatigue protocol (e.g. before, during, and after).
Changes in the phosphocreatine/ATP ratioWithin a day for each experimentThis will be calculated by determining the above concentration of phosphocreatine and ATP at different times of the contraction fatigue protocol (e.g. before, during and after).

Countries

United Kingdom

Contacts

Primary ContactPatrick Tran
patricktranphd@gmail.com02476964000
Backup ContactPatrick Tran
patrick.tran2@uhcw.nhs.uk+442476965689

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026